Testimony Before the FDA’s Antimicrobial Drugs Advisory Committee Meeting about Sulopenem Etzadroxil/Probenecid for Uncomplicated Urinary Tract Infection
In testimony before the FDA’s Antimicrobial Drugs Advisory Committee about oral sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infection in adult women, Public Citizen emphasized our concerns about the significant risk of increasing antimicrobial resistance if the drug was widely used for uncomplicated urinary tract infection, the insufficient evidence that the drug was either a superior drug or needed alternative to existing first line treatments, and the importance of further study of the potential for increased antimicrobial resistance at both the individual and population level.